Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis

Regulatory requirements for claims of mucosal healing in ulcerative colitis (UC) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development.

[1]  J. Wehkamp,et al.  Faculty Opinions recommendation of Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  G. D'Haens,et al.  Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  S. Travis,et al.  Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. , 2017, The Cochrane database of systematic reviews.

[4]  T. Kucharzik,et al.  Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study , 2017, Inflammatory bowel diseases.

[5]  M. Keir,et al.  Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC , 2016, Gut.

[6]  S. Vermeire,et al.  AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial. , 2016, Journal of Crohn's & colitis.

[7]  D. Ge,et al.  Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis , 2016, Alimentary pharmacology & therapeutics.

[8]  M. Neurath,et al.  Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis , 2016, Journal of Crohn's & colitis.

[9]  S. Vermeire,et al.  Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. , 2016, The New England journal of medicine.

[10]  G. D'Haens,et al.  Efficient Early Drug Development for Ulcerative Colitis. , 2016, Gastroenterology.

[11]  B. Sands,et al.  Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. , 2016, Journal of Crohn's & colitis.

[12]  O. Dewit,et al.  Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. , 2016, Gastroenterology.

[13]  S. Travis,et al.  Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. , 2016, Journal of Crohn's & colitis.

[14]  T. Hibi,et al.  Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis , 2015, Journal of Crohn's & colitis.

[15]  T. Hibi,et al.  Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. , 2015, Gastroenterology.

[16]  S. Langenecker,et al.  Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression. , 2015, JAMA psychiatry.

[17]  L. Stitt,et al.  Development and validation of a histological index for UC , 2015, Gut.

[18]  S. Travis,et al.  Development and validation of the Nancy histological index for UC , 2015, Gut.

[19]  S. Travis,et al.  Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials , 2015, Inflammatory bowel diseases.

[20]  G. D'Haens,et al.  Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis , 2015, Alimentary pharmacology & therapeutics.

[21]  Jing Gao,et al.  Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis , 2015, Journal of clinical gastroenterology.

[22]  A. Hart,et al.  Clinical trials in ulcerative colitis: a historical perspective. , 2015, Journal of Crohn's & colitis.

[23]  P. Rutgeerts,et al.  Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis , 2015, Alimentary pharmacology & therapeutics.

[24]  D. Clemmons,et al.  Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. , 2015, Gastroenterology.

[25]  A. Amiot,et al.  Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases , 2015, Therapeutic advances in gastroenterology.

[26]  A. Ford,et al.  IBS-like symptoms in patients with ulcerative colitis , 2015, Clinical and experimental gastroenterology.

[27]  W. Reinisch,et al.  Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study , 2015, Gut.

[28]  Rubin David,et al.  O-001 Budesonide MMX® 9 mg for Inducing Remission in Patients With Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled With Oral 5-ASAs , 2014 .

[29]  J. Panés,et al.  Safety and Activity of Dersalazine Sodium in Patients with Mild-to-moderate Active Colitis: Double-blind Randomized Proof of Concept Study , 2014, Inflammatory bowel diseases.

[30]  Michael Joseph Peterson,et al.  Reproducibility of histological assessments of disease activity in UC , 2014, Gut.

[31]  L. Peyrin-Biroulet,et al.  Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study , 2014, Gut.

[32]  J. Mansfield,et al.  Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial , 2014, The Lancet.

[33]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[34]  P. Rutgeerts,et al.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[35]  P. Rutgeerts,et al.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[36]  T. Hibi,et al.  Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis , 2013, Journal of Gastroenterology.

[37]  D. Altman,et al.  Reliability and initial validation of the ulcerative colitis endoscopic index of severity. , 2013, Gastroenterology.

[38]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[39]  T. Hibi,et al.  Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo‐controlled study , 2013, Alimentary pharmacology & therapeutics.

[40]  P. Rutgeerts,et al.  The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.

[41]  W. Sandborn,et al.  Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study , 2013, Gut.

[42]  S. Travis,et al.  Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study , 2013, Gut.

[43]  A. Zinsmeister,et al.  Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[44]  R. Bagin,et al.  Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. , 2012, Gastroenterology.

[45]  W. Sandborn,et al.  Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.

[46]  B. Sands,et al.  Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. , 2012, Gastroenterology.

[47]  S. Targan,et al.  Abatacept for Crohn's disease and ulcerative colitis. , 2012, Gastroenterology.

[48]  J. Mansfield,et al.  A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis , 2012, Gut.

[49]  T. Matsui,et al.  Double‐blind, placebo‐controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid‐refractory ulcerative colitis , 2012, Inflammatory bowel diseases.

[50]  B. Warner,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[51]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[52]  L. Colloca,et al.  Harnessing the placebo effect: the need for translational research , 2011, Philosophical Transactions of the Royal Society B: Biological Sciences.

[53]  Steven W. Martin,et al.  The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study , 2011, Gut.

[54]  Richard D Riley,et al.  Interpretation of random effects meta-analyses , 2011, BMJ : British Medical Journal.

[55]  S. Schreiber,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[56]  A. Watson,et al.  Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis , 2010, Gut.

[57]  Theo Stijnen,et al.  Random effects meta‐analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data , 2010, Statistics in medicine.

[58]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[59]  G. Firestein,et al.  Regulation of Peripheral Inflammation by the Central Nervous System , 2010, Current rheumatology reports.

[60]  W. Forbes,et al.  Safety and Efficacy of a New 3.3 g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study , 2009, The American Journal of Gastroenterology.

[61]  D. Drossman,et al.  Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome , 2008, BMJ : British Medical Journal.

[62]  J. Ellenberg,et al.  Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. , 2008, Gastroenterology.

[63]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[64]  C. Brensinger,et al.  A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. , 2007, Gastroenterology.

[65]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[66]  M. Kamm,et al.  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[67]  Stefan Schreiber,et al.  A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. , 2007, Gastroenterology.

[68]  S. Targan,et al.  Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial , 2006, Gut.

[69]  T. Matsui,et al.  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis , 2006, Gut.

[70]  E. Chuang,et al.  A Phase II dose ranging, double‐blind, placebo‐controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left‐sided ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[71]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[72]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[73]  S. V. van Deventer,et al.  A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis , 2004, Gut.

[74]  Julian P T Higgins,et al.  Controlling the risk of spurious findings from meta‐regression , 2004, Statistics in medicine.

[75]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[76]  P. Rutgeerts,et al.  Interferon β-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study , 2003 .

[77]  A. Forbes,et al.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial , 2003, Gut.

[78]  B. Sands,et al.  Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial , 2003, Alimentary pharmacology & therapeutics.

[79]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[80]  Fabrizio Benedetti,et al.  Response expectancies in placebo analgesia and their clinical relevance , 2001, Pain.

[81]  S D Walter,et al.  A comparison of methods to detect publication bias in meta‐analysis , 2001, Statistics in medicine.

[82]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[83]  G. Greenberg,et al.  An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC) , 2000 .

[84]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[85]  M. Cheang,et al.  Quantification of the placebo response in ulcerative colitis. , 1997, Gastroenterology.

[86]  J. Baker,et al.  Treatment of left‐sided ulcerative colitis with butyrate enemas: a controlled trial , 1996, Alimentary pharmacology & therapeutics.

[87]  C H Schmid,et al.  Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. , 1995, Journal of clinical epidemiology.

[88]  K. Batts,et al.  A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. , 1994, Gastroenterology.

[89]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[90]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.